Smart Biotech Scientist | Master Bioprocess CMC Development, Biologics Manufacturing & Scale-up for Busy Scientists

About Smart Biotech Scientist | Master Bioprocess CMC Development, Biologics Manufacturing & Scale-up for Busy Scientists

The go-to CMC and biomanufacturing podcast for bioprocess development scientists and CMC leaders scaling biologics into regulatory-ready therapies with less trial and error. Practical, execution-focused, and strategic guidance on CMC development, tech transfer, scale-up, GMP readiness, CDMO partnerships, and manufacturing economics for biologics, cell and gene therapies, cultivated meat, and biomaterials. Hosted by Dr. David Brühlmann, CMC strategist, former Bioprocess Innovation Manager at Merck, PhD in glycoengineering, and close to 20 years of biomanufacturing experience. Smart Biotech Scientist delivers actionable insights for the people doing the hard work of turning promising molecules into scalable, regulatory-ready therapies. This podcast is for you if: You are a process development scientist or CMC lead managing a technology transfer, scale-up, or CDMO partnership You are a biologics developer working on upstream or downstream process development, cell culture optimization, or GMP manufacturing readiness You are a biotech founder preparing for an IND filing or Series A fundraise, and need a CMC strategy that holds up under investor and regulatory scrutiny You are building or advising an early-stage biopharma team and need to make smart manufacturing decisions with limited resources What you will learn: CMC strategy and regulatory planning, bioprocess scale-up from lab to clinical and commercial manufacturing, cell culture process development and media optimization, technology transfer best practices, CDMO selection and partnership management, hybrid modeling, manufacturing economics, continuous manufacturing, digitization, and Industry 4.0 in biopharma. Top 10 life sciences podcast with 200+ episodes and guests from Merck, FUJIFILM Irvine Scientific, Cytiva, KBI Biopharma, Eppendorf, and biotech innovators worldwide. New episodes released weekly. Subscribe and join 400+ biotech leaders already using these insights to accelerate development, reduce manufacturing costs, and de-risk scale-up. Next Steps: Get the 5-day CMC email course: https://smartbiotechscientist.com/#cmc (https://smartbiotechscientist.com/#cmc) Visit the website: https://smartbiotechscientist.com (https://smartbiotechscientist.com) Email us: hello@bruehlmann-consulting.com (mailto:hello@bruehlmann-consulting.com)

Publisher

David Brühlmann - CMC Development Leader, Bioprocess Expert, Business Strategist

Category

science

Language

en

Explicit

No

First episode

31 Oct 2023

Latest episode

22 Oct 2026

Latest episodes

253 of 301 episodes have a transcript.

1. 

   22 Oct 2026TRANSCRIPT

   298: 10,000 Structures Are Not Enough: The Data Gap Limiting De Novo Antibody Design with David Younger - Part 2

   David Brühlmann interviews David Younger, CEO of A-Alpha Bio, about the critical data gap limiting de novo antibody design and proposes a collaborative solution.

2. 

   20 Oct 2026TRANSCRIPT

   297: 10,000 Structures Are Not Enough: The Data Gap Limiting De Novo Antibody Design with David Younger - Part 1

   Host David Brühlmann interviews David Younger, CEO of A-Alpha Bio, about the critical data gap hindering de novo antibody design and the path to achieving millions of necessary structures.

3. 

   15 Oct 2026TRANSCRIPT

   296: Neither Small Molecule nor Biologic: The Cyclodextrin Dimer CMC Challenge with Matthew O'Connor - Part 2

   CEO Matthew O'Connor discusses Cyclarity Therapeutics' innovative cyclodextrin-based approach to reversing cardiovascular disease with host David Brühlmann in this interview.

Inside a recent episode

298: 10,000 Structures Are Not Enough: The Data Gap Limiting De Novo Antibody Design with David Younger - Part 2

Published 22 Oct 2026 · Transcript excerpt

[…] And our answer to this challenge is a data consortium. So the general mechanics of this consortium are that model builders, pharmas, AI labs can join this consortium and they essentially pay quarterly for the opportunity to design an alpha-seq experiment. So a million affinity measurements every quarter. And instead of them just getting their data back, we pull all of the data from the consortium and we send it to every consortium member. A Alpha also contributes our own experimental designs that we perform. We add that to the mix and we send that out to the consortium members as well. So the ability for this type of a model to scale is really, really exciting. […]

Who has been a guest on Smart Biotech Scientist | Master Bioprocess CMC Development, Biologics Manufacturing & Scale-up for Busy Scientists

Names identified in recent episode analyses. Showing up to five guests.

• David Younger
• Matthew O'Connor
• Christian Witz
• John Bonham-Carter
• Sandra Núñez

Reach and audience

Public platform figures. Ratings count people who left a rating, not total listeners.

YouTube views

12,340

Score snapshot 15 Sept 2025

Apple Podcasts (US)

5.0 / 5

10 ratings

Spotify

5.0 / 5

14 ratings

Podcast Authority Score: 78 / 100

A composite of feed quality, social presence, YouTube performance and engagement. Read the methodology.

Quality

92

Social presence

0

YouTube

76

Engagement

82

Contact Smart Biotech Scientist | Master Bioprocess CMC Development, Biologics Manufacturing & Scale-up for Busy Scientists

Guest appearances

Books guests

Based on episode analysis; this does not confirm that the show is currently accepting guests.

Shows with a similar audience

• 

  The Indicator from Planet Money

• 

  Planet Money

• 

  The Daily

• 

  Bioprocessing Unfiltered

• 

  The Intelligence from The Economist

• 

  TED Radio Hour

Questions about Smart Biotech Scientist | Master Bioprocess CMC Development, Biologics Manufacturing & Scale-up for Busy Scientists